Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (Q34050239)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial |
scientific article |
Statements
1 reference
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (English)
1 reference
John Hainsworth
1 reference
Roy S Herbst
1 reference
Rafat Ansari
1 reference
Frederique Bustin
1 reference
Patrick Flynn
1 reference
Lowell Hart
1 reference
Gregory A Otterson
1 reference
Gordana Vlahovic
1 reference
Chang-Heok Soh
1 reference
Paula O'Connor
1 reference
Identifiers
1 reference